{
    "nct_id": "NCT03945019",
    "official_title": "A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease",
    "inclusion_criteria": "* Patient is male or female aged 18 to 75 years, inclusive.\n* Patient who has moderately to severely active CD with a score on the CDAI of 220 to 450 points\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Patient who has previously received either a TNFα inhibitor or biological agent within 5 half-lives\n* Patient who has previously demonstrated inadequate response or intolerance to TNFα inhibitors for the treatment of CD.",
    "miscellaneous_criteria": ""
}